US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
pharma · No medical condition.
BIAL - Portela
BIAL - Portela & Ca
BIAL - Portela drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
TROFA, PT HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- TROFA, PT
- Programs
- 4
- Drugs
- 9
- Patents
- 25
BIAL - Portela pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
BIAL - Portela drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to BIAL - Portela in public FDA and regional records. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
dabigatran etexilate
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in BIAL - Portela's portfolio. Mechanism: Thrombin inhibitor.
- Mechanism
- Thrombin inhibitor
-
midazolam
Nervous system (N05)US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to BIAL - Portela in public FDA and regional records.
-
Development asset linked to BIAL - Portela in public FDA and regional records.
-
Development asset linked to BIAL - Portela in public FDA and regional records.
-
Development asset linked to BIAL - Portela in public FDA and regional records.